FDA Expedited Programs: Fast Track vs Breakthrough vs AA

Every biotech press release throws around the same four phrases: Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. Almost no retail investor can tell them apart, and almost no one knows which one actually moves a stock. Here is the map.

The short version: Fast Track and Breakthrough Therapy are designations that make development smoother. Accelerated Approval is an approval pathway that gets a drug to market on a proxy measurement. Priority Review is a shorter review clock. They stack on top of each other, but only some of them are a genuine tradeable edge. The FDA’s own one-page comparison is the reference, at fda.gov.

Fast Track

Fast Track designation is for a drug that treats a serious condition and has the potential to address an unmet medical need. The key word is potential. A company can get Fast Track on nonclinical data, meaning animal or lab work, before it has ever treated a human.

What it gets you: more frequent meetings with the FDA, more written communication, and rolling review, which lets the FDA start reviewing sections of the application as they are completed instead of waiting for the whole thing.

What it does not get you: a faster review clock. Fast Track does not shorten the 10-month standard review by itself. It makes the path smoother, not shorter.

Breakthrough Therapy

Breakthrough Therapy designation is the stronger version, and it is the clearest signal of FDA enthusiasm a company can print in a press release.

To qualify, a drug must treat a serious condition and have preliminary clinical evidence, meaning human trial data, showing it may deliver a substantial improvement on a clinically significant endpoint over what is already available. Animal data is not enough. A drug has to actually work in people.

What it gets you: everything Fast Track gets, plus intensive senior-FDA guidance, a cross-disciplinary project lead, and an organizational commitment to an efficient development program. When the FDA grants Breakthrough Therapy, it is essentially saying “we want this drug to get approved.”

The distinction from Fast Track is the data bar. Fast Track needs potential. Breakthrough needs demonstrated human evidence of a big improvement. A drug can get Fast Track on a mechanism and Breakthrough only after it proves itself in a trial.

Accelerated Approval

Accelerated Approval is not a designation. It is a different approval pathway, and it is the one with real downside risk.

Under accelerated approval, the FDA approves a drug based on a surrogate endpoint, a measurement reasonably likely to predict clinical benefit, rather than waiting for proof the drug actually helps patients live longer or better. The company then must run a confirmatory trial to verify the benefit. See the deep dive on accelerated approval.

The catch: if the confirmatory trial fails, the FDA can withdraw the drug. The FDORA law of 2022 gave the FDA faster withdrawal authority, and roughly 15% of oncology accelerated approvals have eventually been pulled. When a biotech trades on accelerated approval data alone, you are holding withdrawal risk.

Priority Review

Priority Review is the simplest one: it shortens the review clock from the standard 10 months to 6 months. It is granted when a drug would be a significant improvement over existing therapies.

Priority Review is the designation that most directly maps to a date. A 6-month clock means a PDUFA date that is four months sooner, which matters for traders. But it does not make approval more likely, just faster. See the priority vs standard review guide.

RMAT and the Priority Review Voucher

Two more terms show up in gene and cell therapy press releases.

• RMAT (Regenerative Medicine Advanced Therapy): a designation for cell and gene therapies that treat a serious condition and have preliminary clinical evidence of potential to address unmet need. Unlike Breakthrough, it does not require proof of substantial improvement over existing therapies. It gets the therapy extra FDA attention and can support accelerated approval.
• PRV (Priority Review Voucher): a transferable coupon that converts a standard 10-month review into a 6-month priority review. It is a sellable asset, worth roughly $100 million at the median, and Rocket Pharmaceuticals sold one for $180 million in April 2026. See the PRV guide.

The comparison table

Designation	What it requires	What it gets you	Moves the stock?
Fast Track	Serious condition + potential unmet need (nonclinical or clinical data)	More meetings, rolling review	Mild, mostly noise
Breakthrough Therapy	Serious condition + clinical evidence of substantial improvement	All Fast Track benefits + senior-FDA guidance	Yes, meaningful
Accelerated Approval	Surrogate endpoint + confirmatory trial required	Approval years early	Yes, but carries withdrawal risk
Priority Review	Significant improvement over existing therapy	6-month clock instead of 10	Yes, pulls the date forward
RMAT	Cell/gene therapy + potential unmet need	Extra attention, AA eligibility	Mild
PRV	Awarded after certain approvals	Transferable ~$100M coupon	Yes, real cash

What it means for the stock

Here is the verdict, because the point is to know which phrase to care about.

Breakthrough Therapy and Priority Review are the genuine edges. Breakthrough means the FDA has seen human data and likes it, which is the only pre-approval signal based on demonstrated human efficacy. Priority Review pulls the PDUFA date forward, which compresses the catalyst into a nearer, tradeable window.

Fast Track is mostly decoration. Almost every oncology drug gets it. It signals the company filled out a form, not that the FDA believes in the drug.

Accelerated Approval is a double-edged sword. It gets a drug to market early, which is a real catalyst, but it attaches a confirmatory-trial overhang that can later destroy the stock.

The press releases that move a stock stack Breakthrough Therapy, Priority Review, and a near PDUFA date together. Daiichi Sankyo and AstraZeneca ran exactly that play with ENHERTU: Breakthrough Therapy designation in December 2025, Priority Review, and a July 7, 2026 PDUFA date it hit on schedule. Cogent Biosciences (COGT) is running the same play with bezuclastinib ahead of its November 30, 2026 PDUFA date. When you see all three, the regulatory path is aligned. When you see only Fast Track, the company is dressing up a routine milestone.

Common mistakes

• Treating Fast Track as bullish news. It is table stakes in oncology. A Fast Track press release is not a catalyst.
• Ignoring the accelerated approval confirmatory risk. A drug approved on a surrogate can still be withdrawn. The approval is real but conditional.
• Confusing Priority Review with higher odds. It is a faster clock, not a higher chance of approval. A 6-month review can still end in a CRL.
• Assuming designations are permanent. Fast Track and Breakthrough can be rescinded if the data stops supporting them.

Final checklist

• Check which designation is actually being announced, not just “expedited”
• Fast Track alone is noise; Breakthrough Therapy is signal
• If it is accelerated approval, find the confirmatory trial and its readout date
• Priority Review shortens the clock, it does not raise the odds
• A PRV is real cash for the company, worth watching for small caps